Integrated genomic and transcriptomic analysis to predict FOLFIRINOX response in metastatic pancreatic ductal adenocarcinoma

被引：0
|
作者：
Lansbergen, Marjolein Francisca
Dings, Mark Pui Gien
Koster, Jan
Wilmink, Johanna
Van Laarhoven, Hanneke W. M.
Bijlsma, Maarten F.
机构：
[1] Amsterdam UMC, Amsterdam, Netherlands
[2] Amsterdam UMC, Ctr Expt Mol Med, Amsterdam, Netherlands
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4153
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Induction FOLFIRINOX for patients with locally unresectable pancreatic ductal adenocarcinoma
    McIntyre, Caitlin A.
    Cohen, Noah A.
    Goldman, Debra A.
    Gonen, Mithat
    Sadot, Eran
    O'Reilly, Eileen M.
    Varghese, Anna M.
    Yu, Kenneth H.
    Balachandran, Vinod P.
    Soares, Kevin C.
    D'Angelica, Michael, I
    Drebin, Jeffrey A.
    Kingham, T. P.
    Allen, Peter J.
    Wei, Alice C.
    Jarnagin, William R.
    JOURNAL OF SURGICAL ONCOLOGY, 2022, 125 (03) : 425 - 436
  • [22] Adverse events in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) who received FOLFIRINOX in the first line
    Kim, George P.
    Silver, Michelle
    Sanders, Chad
    Cockrum, Paul
    MacEwan, Joanna P.
    Duncan, Dan
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [23] A Chemoresistance Signature to Predict FOLFIRINOX Sensitivity in Pancreatic Adenocarcinoma
    Gao, Zachary
    Dong, Jiangling
    Janakiraman, Harinarayanan
    Choi, Jasmine
    Erstad, Derek
    Fisher, William
    Van Buren, George
    Kang, Sung Wook
    Lee, Hyun-Sung
    Camp, E. Ramsay
    ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (01) : S27 - S27
  • [24] Pancreatic ductal adenocarcinoma: metastatic disease
    Munoz Martin, A. J.
    Adeva, J.
    Martinez-Galan, J.
    Reina, J. J.
    Hidalgo, M.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2017, 19 (12): : 1423 - 1429
  • [25] Pancreatic ductal adenocarcinoma: metastatic disease
    A. J. Muñoz Martín
    J. Adeva
    J. Martínez-Galán
    J. J. Reina
    M. Hidalgo
    Clinical and Translational Oncology, 2017, 19 : 1423 - 1429
  • [26] Adjuvant FOLFIRINOX in Patients with Resected Pancreatic Ductal Adenocarcinoma: A Cost-effectiveness Analysis
    Hersh, A. R.
    Buuck, T.
    Wagner, J.
    Kardosh, A.
    Caughey, A.
    Mayo, S. C.
    Billingsley, K. G.
    ANNALS OF SURGICAL ONCOLOGY, 2020, 27 (SUPPL 1) : S45 - S45
  • [27] Alterations in Driver Genes Are Associated with Response to Neoadjuvant Folfirinox in Patients with Nonmetastatic Pancreatic Ductal Adenocarcinoma
    Ecker, Brett L.
    Janssen, Quisette
    Tao, Alice
    Tansey, Wesley
    D'Angelica, Michael
    Drebin, Jeffrey A.
    Jarnagin, William R.
    Kingham, T. Peter
    Soares, Kevin
    Wei, Alice C.
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2021, 233 (05) : S139 - S139
  • [28] Integrated clinico-genomic characterization of pancreatic ductal adenocarcinoma in an Asian population
    Jung, Kwangrok
    Jung, Jae Hyup
    Ahn, Jinwoo
    Kim, Bomi
    Lee, Jong-Chan
    Kim, Jaihwan
    Hwang, Jin-Hyeok
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [29] Response in BRCA1 mutation carrier with metastatic pancreatic adenocarcinoma treated with FOLFIRINOX
    Campoverde, Leticia Estefania
    Batalini, Felipe
    Bulushi, Yarab
    Bullock, Andrea
    BMJ CASE REPORTS, 2022, 15 (04)
  • [30] Erratum zu: FOLFIRINOX beim duktalen Adenokarzinom des PankreasErratum to: FOLFIRINOX for pancreatic ductal adenocarcinoma
    Hakan Alakus
    Michael Korenkov
    Fabian Kütting
    Christiane Bruns
    Der Onkologe, 2019, 25 (8): : 728 - 728
12345